And we expect to continue to grow in the mid to high-single digits in 2022.
This is on top of 6% core growth last year.
For the year, the Diagnostics and Clinical business grew 15% for the year after declining slightly by 1% in 2020.
The strong growth in our Chemical and Energy business continues as we delivered 11% growth in the quarter.
For Q1, we are expecting revenue to range from $1.64 billion to $1.66 billion, representing reported and core growth of 5.9% to 7.2%.
Our full year operating margin was up 200 basis points.
And for the year, Americas led the way with 21% growth, followed by China at 13% and Europe at 12%.
